Evaluating the Efficacy and Safety of the Lower Dose of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients With Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation- KMM103 Study
Clinical trial NCT01255527 · UNKNOWN
Trial details
- NCT number
- NCT01255527
- Sponsor
- Yonsei University
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2010-10-01
- Primary completion
- 2014-12-01
- Enrollment
- 53
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.